S2 Episode 4: Cardiovascular Risk in Patients With Psoriatic Arthritis
Manage episode 341741385 series 3291808
Drs Stanley Cohen and Atul Deodhar discuss cardiovascular risk in patients with psoriatic arthritis and the impact of effective treatment.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/970784). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.
Resources
Prevalence of Metabolic Syndrome in Psoriatic Arthritis: Systematic Literature Review and Results From the CARMA Cohort https://journals.lww.com/jclinrheum/Abstract/2022/03000/Prevalence_of_Metabolic_Syndrome_in_Psoriatic.22.aspx
Metabolic Syndrome https://emedicine.medscape.com/article/165124-overview
What Is the Framingham Risk Score (FRS)? https://www.medscape.com/answers/2500032-166149/what-is-the-framingham-risk-score-frs
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines https://www.sciencedirect.com/science/article/pii/S0735109713060312?via%3Dihub
What Is the Systematic Coronary Risk Evaluation (SCORE)? https://www.medscape.com/answers/2500032-166154/what-is-the-systematic-coronary-risk-evaluation-score
Anti-inflammatory Therapy With Canakinumab for Atherosclerotic Disease https://www.nejm.org/doi/pdf/10.1056/nejmoa1707914
Colchicine in Patients With Chronic Coronary Disease https://www.nejm.org/doi/10.1056/NEJMoa2021372
The Effects of Tumour Necrosis Factor Inhibitors, Methotrexate, Non-steroidal Anti-inflammatory Drugs and Corticosteroids on Cardiovascular Events in Rheumatoid Arthritis, Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta-analysis https://ard.bmj.com/content/74/3/480
Psoriatic Arthritis Medication https://emedicine.medscape.com/article/2196539-medication
Efficacy and Safety of Selective TYK2 Inhibitor, Deucravacitinib, in a Phase II Trial in Psoriatic Arthritis https://ard.bmj.com/content/81/6/815
FDA Requires Warnings About Increased Risk of Serious Heart-Related Events, Cancer, Blood Clots, and Death for JAK Inhibitors That Treat Certain Chronic Inflammatory Conditions https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death
18 ตอน